Bristol Myers Squibb Company $BMY Shares Newly Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 193,465 shares of the biopharmaceutical company’s stock, valued at approximately $12,072,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp increased its position in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA acquired a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after purchasing an additional 119,690 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Bristol Myers Squibb by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after purchasing an additional 520,330 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Citigroup restated a “neutral” rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Morgan Stanley lowered their price target on shares of Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a report on Friday, October 30th. The Goldman Sachs Group upgraded Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 16th. Jefferies Financial Group reiterated a “buy” rating and issued a $76.00 price target on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Finally, Wells Fargo & Company cut their price objective on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $65.46.

Get Our Latest Report on BMY

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $62.96 on Tuesday. The business has a 50 day moving average of $61.82 and a 200-day moving average of $60.35. The company has a market capitalization of $128.69 billion, a P/E ratio of 13.96, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a 1 year low of $45.26 and a 1 year high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. During the same period last year, the company earned $1.63 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.46 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Julia A. Haller sold 3,800 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their position. The SEC filing for this sale provides additional information. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Featured Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.